Xencor, Inc.

XNCR Healthcare Biotechnology

Xencor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $125.6 million, up 13.7% from fiscal 2024. In the quarter to June 2026, revenue grew 17.5%, EPS grew 29.3% and free cash flow fell 52.9%, each against the same quarter a year earlier.

25.90 0.74 +2.94%
Market cap
$1.9B
P/E
0.0×
Fwd P/E
−7.4×
Dividend yield
—
F-score
3/9
Altman Z
1.73
Beneish M
−2.86
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
5.81 9.05 9.32 11.63
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(28.32) (21.98) (13.42) (21.94)
P/B ratio
1.40 1.79 1.76 2.43
EV/Sales
3.70 5.64 5.98 8.43
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(4.03) (5.09) (3.07) (4.23)
Current Ratio
5.99 6.25 6.57 6.39
Net Debt/EBITDA
10.48 7.85 5.91 13.18
Debt/Equity
0.00 0.19 0.00 0.00
Earnings Yield
(15.09%) (8.10%) (18.99%) (13.48%)
Free Cash Flow Yield
(15.80%) (12.25%) (20.92%) (17.14%)
Free Cash Flow per Share
(0.42) (0.71) (0.91) (0.74)
Book value per Share
8.40 8.56 6.85 6.63
Free Cash Flow
(31.00) (52.85) (68.24) (56.20)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates